Media coverage about Syros Pharmaceuticals (NASDAQ:SYRS) has been trending somewhat positive recently, Accern Sentiment reports. The research firm rates the sentiment of media coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Syros Pharmaceuticals earned a media sentiment score of 0.11 on Accern’s scale. Accern also gave news coverage about the company an impact score of 44.6959548677027 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
Here are some of the media stories that may have impacted Accern’s rankings:
- Zacks: Analysts Anticipate Syros Pharmaceuticals Inc (SYRS) to Post -$0.57 EPS (americanbankingnews.com)
- Q1 2018 EPS Estimates for Syros Pharmaceuticals Inc (SYRS) Lifted by Oppenheimer (americanbankingnews.com)
- Q1 2018 Earnings Estimate for Syros Pharmaceuticals Inc Issued By Wedbush (SYRS) (americanbankingnews.com)
- Syros Pharmaceuticals Inc (SYRS) Receives Average Recommendation of “Buy” from Analysts (americanbankingnews.com)
- Syros Pharmaceuticals (SYRS) Provides Outline of Strategic Priorities and Expected Milestones for 2018 (streetinsider.com)
Several equities analysts recently issued reports on the stock. JMP Securities raised shares of Syros Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $33.00 price objective for the company in a research report on Thursday, September 28th. Cowen reissued a “buy” rating on shares of Syros Pharmaceuticals in a research report on Monday, December 11th. Oppenheimer set a $28.00 price target on shares of Syros Pharmaceuticals and gave the company a “buy” rating in a report on Monday, January 8th. ValuEngine lowered shares of Syros Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, September 22nd. Finally, Zacks Investment Research raised shares of Syros Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, October 17th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and six have issued a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $22.23.
Syros Pharmaceuticals (NASDAQ:SYRS) last announced its quarterly earnings data on Wednesday, November 8th. The company reported ($0.53) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.53). sell-side analysts predict that Syros Pharmaceuticals will post -2.12 EPS for the current year.
In related news, insider Jeremy P. Springhorn purchased 15,000 shares of the firm’s stock in a transaction that occurred on Friday, December 15th. The stock was acquired at an average cost of $9.08 per share, for a total transaction of $136,200.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Srinivas Akkaraju purchased 109,774 shares of the firm’s stock in a transaction that occurred on Thursday, December 14th. The shares were bought at an average price of $9.03 per share, with a total value of $991,259.22. The disclosure for this purchase can be found here. Company insiders own 33.60% of the company’s stock.
About Syros Pharmaceuticals
Syros Pharmaceuticals, Inc is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines.
Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.